NovoCure Stock Performance Snapshot
NovoCure (NVCR) has drawn attention after a recent move in its share price, with the stock last closing at $15.92 and showing mixed return patterns across different time frames.
Over the past week the stock declined 2.3%, while the past month shows a gain of 11.5% and the past 3 months a gain of 25.7%. Year to date, NovoCure is up 21.3%, although the 1 year total return is marginally negative at 0.6%.
See our latest analysis for NovoCure.
The recent 1 day share price return of 3.05% and 7 day share price return of 2.33% sit against a 30 day share price return of 11.48% and 90 day share price return of 25.65%, while the 1 year total shareholder return declined 0.62% and the 3 and 5 year total shareholder returns declined 59.10% and 91.59% respectively. NovoCure’s short term momentum therefore contrasts with a much weaker longer term record.
If NovoCure’s recent rebound has caught your eye, it can be helpful to compare it with other cancer and medical technology players and see how they stack up in the 39 healthcare AI stocks.
NovoCure’s sharp short term rebound sits against years of weaker shareholder returns, so the real question now is whether to step in at around $15.92 or wait for a better entry as the valuation picture unfolds.
Most Popular NovoCure Narrative: 38.9% Undervalued
The most followed narrative on NovoCure sees a fair value of $26.07 against the recent $15.92 share price, framing the current valuation gap as related to execution on growth, profitability and future multiples.
Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, which may drive topline revenue as global cancer incidence changes in the aging population.
Want to understand why this fair value sits above NovoCure's share price? The narrative focuses on earnings, revenue and a future profit multiple that is associated with oncology adoption curves.
Result: Fair Value of $26.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, NovoCure’s story can change quickly if TTFields adoption slows or reimbursement progress stalls. This would directly test this 38.9% undervalued narrative.
Find out about the key risks to this NovoCure narrative.
Next Steps
Conflicted about whether NovoCure’s recent moves signal a turnaround or just a pause in a tougher story? Act while the data is fresh, consider both perspectives, and review the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond NovoCure?
Do not stop with NovoCure. Broaden your watchlist now with fresh stock ideas built from clear fundamentals, dividends and lower risk profiles.
- Spot potential bargains quickly by filtering for companies that combine quality and valuation using the 47 high quality undervalued stocks.
- Identify income ideas by zeroing in on companies with robust payout potential through the 8 dividend fortresses.
- Focus on protecting your capital by looking at companies with steadier risk profiles using the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com